Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Accumulated Expenses (2016 - 2025)

United Therapeutics' Other Accumulated Expenses history spans 17 years, with the latest figure at $72.6 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 22.44% year-over-year to $72.6 million; the TTM value through Dec 2025 reached $72.6 million, down 22.44%, while the annual FY2025 figure was $72.6 million, 22.44% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $72.6 million at United Therapeutics, down from $78.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $154.5 million in Q1 2025 and bottomed at $24.8 million in Q2 2021.
  • The 5-year median for Other Accumulated Expenses is $65.4 million (2022), against an average of $63.7 million.
  • The largest annual shift saw Other Accumulated Expenses tumbled 47.58% in 2021 before it surged 227.2% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $28.4 million in 2021, then rose by 14.44% to $32.5 million in 2022, then soared by 118.46% to $71.0 million in 2023, then soared by 31.83% to $93.6 million in 2024, then dropped by 22.44% to $72.6 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Other Accumulated Expenses are $72.6 million (Q4 2025), $78.3 million (Q3 2025), and $95.1 million (Q2 2025).